ReviewFrontiers in pharmacology2026
Natural drugs modulate MAPK: targets and strategies for liver fibrosis treatment.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis (LF) as a critical pathological stage in the progression of various chronic liver diseases toward cirrhosis and hepatocellular carcinoma, has become a severe global public health challenge posing a serious threat to patient health. Consequently, there is an urgent need to develop novel, highly effective therapeutic drugs and intervention strategies. The application of traditional Chinese medicine (TCM) formulas and natural drugs leveraging their unique advantages of multi-target and multi-pathway mechanisms, is increasingly attracting attention in the field of LF treatment. In recent years, a growing number of studies have focused on the therapeutic value of natural drugs and TCM formulas in treating LF. This review systematically explores the clinical application potential and core therapeutic mechanisms of natural drugs and TCM formulas in LF treatment, covering natural compounds such as flavonoids, terpenoids, and glycosides, as well as TCM formulas like Tianhuang Formula and Yiqu Ronggan Formula. We demonstrate that multiple key bioactive components, such as quercetin, curcumin, and astragaloside IV, exhibit beneficial effects in LF intervention. These effects primarily occur through modulating critical pathogenic drivers including hepatic stellate cell (HSC) activation, inflammatory responses, and oxidative stress. The elucidated therapeutic mechanisms primarily include inhibiting HSC activation and proliferation, regulating inflammatory pathways, alleviating oxidative stress damage, reducing excessive extracellular matrix (ECM) deposition, and restoring liver tissue microenvironment homeostasis. This preclinical evidence supports the potential efficacy of natural drugs and TCM formulas as complementary and alternative treatment options for LF. However, most existing evidence is based on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.